Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Johnson & Johnson at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Johnson & Johnson brings 9 presentations to ASH 2026 in New Orleans, and exhibits at Booth 2913. It presents product theater sessions on myeloma, including a first-in-class treatment and DARZALEX FASPRO with VRd. It also supports symposia on AL amyloidosis and menin inhibitors in leukemia.

OrganizationASH 2026 Attendance
Johnson & Johnson
New Brunswick, NJ
Large pharma
Global healthcare company that develops, makes and sells prescription medicines and medical technologies, including myeloma and other blood cancer therapies.
Booth
Exhibiting at Booth 2913
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice
Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup.
Myeloma · New drugs
Symposium
Fri Dec 11
7:00am–10:00am
Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs
Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity.
Symposium hosted by PeerView Institute for Medical Education
Myeloma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together
Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows.
Myeloma
Symposium
Fri Dec 11
3:00pm–6:00pm
Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors
Menin inhibitors for genetically defined acute myeloid leukemia, covering patient selection, combinations, resistance, and differentiation syndrome.
Leukemias · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice
Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies.
Symposium hosted by National Comprehensive Cancer Network and Decera Clinical Education
Myeloma

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Johnson & Johnson

Tell us what you sell and we’ll find the people at Johnson & Johnson most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction